S 8380 NY
Requires covered entities report to the department of health regarding certain 340B drug discounts
A state bill is a proposed law in a state legislature — separate from the U.S. Congress. Learn more →
Summary
New York bill S 8380 requires covered entities under the federal 340B drug pricing program to report annually to the Department of Health on their use of discounted drugs and patient benefits. Beginning April 1, 2027, covered entities must report acquisition costs, payments received, the percentage of prescriptions using 340B drugs, and what percentage of low-income patients benefit from reduced cost-sharing or sliding fee scales. The report must also include costs for implementing patient benefits from 340B discounts and payments to contract pharmacies and third-party administrators. A corporate officer must certify the accuracy of the report, and the Department of Health must post all reports on a publicly accessible website. The act takes effect immediately.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Official abstract
Requires covered entities report to the department of health regarding certain 340B drug discounts and what percentage of patients benefit from such discounts.
Sponsor (1)
- Siela Bynoe Democratic · primary
4 coauthors / cosponsors
- Leroy Comrie Democratic · cosponsor
- John Liu Democratic · cosponsor
- Kevin S. Parker Democratic · cosponsor
- Lea Webb Democratic · cosponsor
Action history (4)
- Jun 6, 2025 REFERRED TO RULES · upper
- Jan 7, 2026 REFERRED TO HEALTH · upper
- May 12, 2026 AMEND AND RECOMMIT TO HEALTH · upper
- May 12, 2026 PRINT NUMBER 8380A · upper
Text versions (3)
Full text
Full text imported from assembly.state.ny.us
Skip to main content
New York State Assembly Speaker Carl E. Heastie
--> --> -->
Assembly Members
Legislative Info
Public Hearings
Speaker's Press
Assembly Reports
Committees & More
Bill Search Home Laws Legislative Calendar Public Hearing Schedule Assembly Calendars Assembly Committee Agenda Javascript must be enabled to properly view this page.
Bill No.: Summary Actions Committee Votes Floor Votes Memo Text LFIN Chamber Video/Transcript S08380 Summary: BILL NO S08380A   SAME AS SAME AS A06987-A
  SPONSOR BYNOE   COSPNSR COMRIE, LIU, PARKER, WEBB   MLTSPNSR   Add §280-e, Pub Health L   Requires covered entities report to the department of health regarding certain 340B drug discounts and what percentage of patients benefit from such discounts.
Go to top S08380 Text:
STATE OF NEW YORK ________________________________________________________________________
8380--A
2025-2026 Regular Sessions
IN SENATE
June 6, 2025 ___________
Introduced by Sens. BYNOE, LIU, PARKER, WEBB -- read twice and ordered printed, and when printed to be committed to the Committee on Rules -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the public health law, in relation to requiring trans- parency requirements for certain 340B drugs
The People of the State of New York, represented in Senate and Assem- bly, do enact as follows:
1 Section 1. The public health law is amended by adding a new section 2 280-e to read as follows: 3 § 280-e. Accountability to safeguard benefits for vulnerable patients. 4 1. For the purposes of this section, the following terms shall have the 5 following meanings: 6 (a) "340B drug" shall mean a covered outpatient drug, as defined by 42 7 USC § 1396r-8(k)(2), that has been subject to any offer for reduced 8 prices by a manufacturer pursuant to 42 USC § 256b(a)(1), and is 9 purchased by a covered entity. 10 (b) "340B profits" shall mean the difference between aggregated 11 payments received from insurers, payors, or self-paying patients for all 12 340B drugs and the aggregate acquisition cost pay for all 340B drugs. 13 (c) "340B program" shall mean the federal drug pricing program 14 described in 42 USC § 256b. 15 (d) "Charity care" shall have the same meaning as ascribed to such 16 term as is found in line twenty-three of the S-10 Medicare cost work- 17 sheet or any successor form. 18 (e) "Contract pharmacy" shall mean a pharmacy with which a covered 19 entity has contracted to dispense 340B drugs on behalf of such covered 20 entity to patients of such covered entity, whether distributed in 21 person, via mail, or by other means.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD10744-03-6
S. 8380--A 2
1 (f) "Covered entity" shall have the same meaning as under 42 USC § 2 256b(a)(4). Provided, however, a covered entity shall not include a 3 federally qualified health center. 4 (g) "Low-income patient" shall mean a patient of a covered entity with 5 a family income below two hundred percent of the federal poverty guide- 6 lines. 7 2. Beginning April first, two thousand twenty-seven, each covered 8 entity shall report to the department with respect to such covered enti- 9 ty and separately for each offsite outpatient facility associated with 10 such covered entity, in a form and manner as determined by the depart- 11 ment, the following information about the prior year: 12 (a) Delineated by form of insurance or payor type, including but not 13 limited to Medicaid, Medicare, commercial insurance, and uninsured to 14 include: 15 (i) aggregated acquisition costs paid for all 340B drugs; 16 (ii) aggregated payments received from insurers, payors, and self-pay- 17 ing patients for all 340B drugs; 18 (iii) the total number of prescriptions and percentage of the covered 19 entity's prescriptions that were filled with 340B drugs; and 20 (iv) the percentage of patients served by a sliding fee scale for 340B 21 drugs at the point of sale for low-income patients. 22 (b) The total operating costs for such covered entity, and itemized 23 costs for: 24 (i) implementing direct pass through of 340B profits to patients in 25 the form of lower cost sharing for 340B drugs at the point of dispensing 26 or administration; 27 (ii) implementing a sliding fee scale for 340B drugs at the point of 28 sale for low-income patients; and 29 (iii) charity care. 30 (c) The total payments made to: 31 (i) contract pharmacies for 340B program related services and other 32 functions; 33 (ii) third-party administrators for managing any components of such 34 covered entity's 340B program; and 35 (iii) any other third parties in connection with 340B program-related 36 compliance, legal, educational, and/or administrative costs. 37 (d) The total number of contract pharmacies, including: 38 (i) the number of contract pharmacies located out-of-state and the 39 states in which such out-of-state pharmacies are located; 40 (ii) the total number of prescriptions and the percentage of the 41 covered entity's prescriptions that were filled at contract pharmacies, 42 delineated by in-state and out-of-state contract pharmacies; 43 (iii) the total remuneration paid to or retained by contract pharma- 44 cies or their affiliates for any 340B program-related services performed 45 on behalf of the covered entity; and 46 (iv) the percentage change in total remuneration paid to or retained 47 by contract pharmacies or their affiliates as described in subparagraph 48 (iii) of this paragraph compared to the prior year. 49 3. An officer of a covered entity shall certify the completeness and 50 accuracy of the report submitted pursuant to subdivision two of this 51 section. 52 4. The department shall post all reports submitted by covered entities 53 pursuant to subdivision two of this section on a publicly accessible 54 website. 55 § 2. This act shall take effect immediately.
Go to top
Sitemap
Request Information
Directions and Maps
Comments
Data from OpenStates. View on OpenStates →
Comments